IRF5 and chronic neutrophilic leukemia: The IRF5 regulon signature indicated reduced sensitivity to dexamethasone and high sensitivity to venetoclax (Gower et al., 2025), which may provide insight into novel treatment choices for CNL, especially in patients with hyperleukocytosis.